3 Companies Rising on Good News for Tuesday 25th April 2023
Episode 1361, Apr 25, 2023, 11:19 AM
3 Companies Rising on Good News for Tuesday 25th April 2023
1. Eckoh #ECK - FY23 Trading Update & Notice of Results
The Board expects revenue and adjusted operating profit to be significantly ahead of the prior year with revenues of approximately £39m (FY22 £31.8m) and adjusted operating profit of at least £7.6m (FY22 £5.2m), which is slightly ahead of market expectations.
The Group also saw good cash generation with net cash of £5.7m at the end of the period (FY22 £2.8m), also ahead of market expectations.
2. N4 Pharma #N4P - siRNA update
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are very pleased with these in vitro results for Nuvec® loaded with EGFR and BCL-2, which show that the first investigated dose produces comparable cellular apop-to-sis to two commercially available products.
"We also now have the assay established to complete the dose response expression work for BCL-2, but we already know that BCL-2 must be expressed, as the cell apoptosis work has shown that it knocks down the gene to produce cell death."
3. Whitbread #WTB - Preliminary Results Announcement
Significant profit uplift to above pre-pandemic levels, driven by Premier Inn UK that continues to outperform the UK midscale and economy ('M&E') market
We are making good progress in Germany, with 51 hotels open, giving us confidence that we can achieve our long-term target of 10-14% return on our £1bn of committed capital
Confidence in outlook reflected with initial share buy-back of £300m, to be completed during H1 FY24
1. Eckoh #ECK - FY23 Trading Update & Notice of Results
The Board expects revenue and adjusted operating profit to be significantly ahead of the prior year with revenues of approximately £39m (FY22 £31.8m) and adjusted operating profit of at least £7.6m (FY22 £5.2m), which is slightly ahead of market expectations.
The Group also saw good cash generation with net cash of £5.7m at the end of the period (FY22 £2.8m), also ahead of market expectations.
2. N4 Pharma #N4P - siRNA update
Nigel Theobald, Chief Executive Officer of the Company, commented:
"We are very pleased with these in vitro results for Nuvec® loaded with EGFR and BCL-2, which show that the first investigated dose produces comparable cellular apop-to-sis to two commercially available products.
"We also now have the assay established to complete the dose response expression work for BCL-2, but we already know that BCL-2 must be expressed, as the cell apoptosis work has shown that it knocks down the gene to produce cell death."
3. Whitbread #WTB - Preliminary Results Announcement
Significant profit uplift to above pre-pandemic levels, driven by Premier Inn UK that continues to outperform the UK midscale and economy ('M&E') market
We are making good progress in Germany, with 51 hotels open, giving us confidence that we can achieve our long-term target of 10-14% return on our £1bn of committed capital
Confidence in outlook reflected with initial share buy-back of £300m, to be completed during H1 FY24